Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) were down 49.5% during mid-day trading on Monday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during mid-day trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Price Performance
The business has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Investing In Preferred Stock vs. Common Stock
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- What is a Secondary Public Offering? What Investors Need to Know
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- The How And Why of Investing in Oil Stocks
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
